Getinge AB stock (SE0000202624): CEO share purchase highlights insider confidence after US patent setback

Getinge AB, the Swedish medical technology group listed on Nasdaq Stockholm, stayed in focus on 05/29/2026 after CEO Mattias Perjos acquired 25,000 B shares at SEK 187.70 each, a purchase of roughly SEK 4.7 million that drew renewed attention to the stock’s valuation in the wake of a recent US patent ruling, according to Finansinspektionen data reported by MarketScreener as of 05/29/2026.

The stock traded around SEK 187.70 on 05/29/2026 and last closed at SEK 188.50 on Nasdaq Stockholm under the ticker GETI B, leaving it below an average analyst target of SEK 224.70 cited by MarketScreener as of 05/29/2026, while domestic media also linked the insider buy to recent volatility after a US patent-related setback reported earlier in May, as summarized by ad-hoc-news.de as of 05/30/2026.

As of: 05/30/2026

By the editorial team - specialized in equity coverage.

Getinge AB: core business model

Getinge AB focuses on supplying hospitals and life science customers with equipment and integrated solutions for acute care, surgical workflows, and contamination control, with demand largely tied to procedure volumes, intensive care capacity, and capital investment cycles in global healthcare systems.

Insider activity and ownership structure

The latest insider transaction reported by Sweden’s Finansinspektionen shows CEO Mattias Perjos buying 25,000 Getinge B shares on 05/29/2026 at SEK 187.70 per share, for a total consideration of SEK 4,692,500, according to a summary from MarketScreener as of 05/29/2026.

Market data compiled by MarketScreener as of 05/29/2026 indicate that Getinge B last traded at SEK 188.50 on Nasdaq Stockholm following the insider purchase, with the company positioned among Swedish healthcare equipment peers and the CEO’s buy classified among notable recent insider acquisitions in Sweden-based listings.

Conclusion

The SEK 4.7 million share purchase by Getinge AB’s CEO on 05/29/2026 provides a fresh insider signal at a time when the Swedish medtech company’s valuation has been in focus following a US patent-related setback. With the stock trading just below SEK 190 on Nasdaq Stockholm yet sitting under an average target price reported by MarketScreener, the transaction adds an additional data point for investors assessing how Getinge AB balances legal risks with its positioning in acute care therapies and life science equipment.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.